Retinagenix Therapeutics   Report issue

For profit Phase 3
Founded: Seattle WA United States (2019)

Organization Overview

First Clinical Trial
2020
NCT04311112
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Retinagenix Therapeutics

Active Ingredients

Drugs in Phase 3 Trials (1)

zuretinol (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Retinal Diseases (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1